MX2023013364A - Regimenes de dosificacion de venetoclax para usarse en el tratamiento de los sindromes mielodisplasicos en combinacion con azacitidina. - Google Patents
Regimenes de dosificacion de venetoclax para usarse en el tratamiento de los sindromes mielodisplasicos en combinacion con azacitidina.Info
- Publication number
- MX2023013364A MX2023013364A MX2023013364A MX2023013364A MX2023013364A MX 2023013364 A MX2023013364 A MX 2023013364A MX 2023013364 A MX2023013364 A MX 2023013364A MX 2023013364 A MX2023013364 A MX 2023013364A MX 2023013364 A MX2023013364 A MX 2023013364A
- Authority
- MX
- Mexico
- Prior art keywords
- venetoclax
- azacitidine
- combination
- myelodysplastic syndromes
- dosing regimens
- Prior art date
Links
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title abstract 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 title abstract 2
- 229960002756 azacitidine Drugs 0.000 title abstract 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001183 venetoclax Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163201749P | 2021-05-11 | 2021-05-11 | |
| PCT/US2022/028429 WO2022240786A1 (en) | 2021-05-11 | 2022-05-10 | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013364A true MX2023013364A (es) | 2023-11-27 |
Family
ID=84028499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013364A MX2023013364A (es) | 2021-05-11 | 2022-05-10 | Regimenes de dosificacion de venetoclax para usarse en el tratamiento de los sindromes mielodisplasicos en combinacion con azacitidina. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220378811A1 (https=) |
| EP (1) | EP4337183A4 (https=) |
| JP (1) | JP2024517318A (https=) |
| KR (1) | KR20240006659A (https=) |
| CN (1) | CN117642161A (https=) |
| AU (1) | AU2022273023A1 (https=) |
| BR (1) | BR112023023677A2 (https=) |
| CA (1) | CA3219760A1 (https=) |
| IL (1) | IL308321A (https=) |
| MX (1) | MX2023013364A (https=) |
| WO (1) | WO2022240786A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10052346B2 (en) * | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| KR20220004669A (ko) * | 2019-04-29 | 2022-01-11 | 이뮤노젠 아이엔씨 | 항-cd123 면역접합체를 포함하는 치료적 조합물 |
| JP2022537551A (ja) * | 2019-06-20 | 2022-08-26 | セルジーン・クオンティセル・リサーチ・インコーポレイテッド | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| WO2021037933A1 (en) * | 2019-08-28 | 2021-03-04 | Astrazeneca Ab | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer |
-
2022
- 2022-05-10 IL IL308321A patent/IL308321A/en unknown
- 2022-05-10 WO PCT/US2022/028429 patent/WO2022240786A1/en not_active Ceased
- 2022-05-10 US US17/741,359 patent/US20220378811A1/en not_active Abandoned
- 2022-05-10 JP JP2023569885A patent/JP2024517318A/ja active Pending
- 2022-05-10 AU AU2022273023A patent/AU2022273023A1/en not_active Abandoned
- 2022-05-10 CA CA3219760A patent/CA3219760A1/en active Pending
- 2022-05-10 EP EP22808145.1A patent/EP4337183A4/en not_active Withdrawn
- 2022-05-10 KR KR1020237042682A patent/KR20240006659A/ko active Pending
- 2022-05-10 BR BR112023023677A patent/BR112023023677A2/pt unknown
- 2022-05-10 MX MX2023013364A patent/MX2023013364A/es unknown
- 2022-05-10 CN CN202280048997.0A patent/CN117642161A/zh not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022273023A1 (en) | 2023-11-23 |
| US20220378811A1 (en) | 2022-12-01 |
| EP4337183A4 (en) | 2025-04-23 |
| KR20240006659A (ko) | 2024-01-15 |
| WO2022240786A1 (en) | 2022-11-17 |
| EP4337183A1 (en) | 2024-03-20 |
| JP2024517318A (ja) | 2024-04-19 |
| IL308321A (en) | 2024-01-01 |
| CA3219760A1 (en) | 2022-11-17 |
| CN117642161A (zh) | 2024-03-01 |
| BR112023023677A2 (pt) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
| MX2025000105A (es) | Inhibidor de kras g12c para el tratamiento del cancer | |
| CO2023018231A2 (es) | Restos de administración terapéutica novedosos y usos de estos | |
| MX2016007851A (es) | Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos. | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| CR20160271A (es) | Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco | |
| MX2022007652A (es) | Derivados espiráncos sustituidos de cadena lineal. | |
| CO2024003949A2 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| BR112016007479A2 (pt) | regimes de dosagem de imunoconjugado de anti-folr1 | |
| BR112019004691A2 (pt) | inibidores bicíclicos em espiro da interação menina-mll | |
| BR112023021761A2 (pt) | Regime de dosagem de anti-ifnar1 para injeção subcutânea | |
| UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
| BR112018076639A2 (pt) | quimioterapias de combinação | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| MX2021005878A (es) | Modulador de empalme de herboxidieno de conjugados de anticuerpo-farmaco y metodos de uso. | |
| CL2020000508A1 (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos. | |
| MX2020010417A (es) | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret. | |
| MX2019011620A (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| MX2019014923A (es) | Régimen de dosificación. | |
| MX2023013364A (es) | Regimenes de dosificacion de venetoclax para usarse en el tratamiento de los sindromes mielodisplasicos en combinacion con azacitidina. | |
| BR112023023638A2 (pt) | Regimes de dosagem de venetoclax para uso no tratamento de síndromes mielodisplásicas em combinação com um inibidor de cyp3a e azacitidina | |
| CO2022007501A2 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
| MX2018015916A (es) | Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. | |
| CO2020001887A2 (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático |